Mesothelial tumors are classified into benign or preinvasive tumors, and mesotheliomas.
The benign or preinvasive group includes adenomatoid tumors, well-differentiated papillary …

The 2015 WHO classification of pleural mesotheliomas includes three major histologic
subtypes—epithelioid, sarcomatoid, and biphasic. Recent genomic data has supported the …

Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

Malignant pleural mesothelioma is an aggressive, incurable cancer that is usually caused by
asbestos exposure several decades before symptoms arise. Despite widespread prohibition …

Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for
Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic …

Immunotherapy has transformed lung cancer care in recent years. In addition to providing
durable responses and prolonged survival outcomes for a subset of patients with heavily …

Importance Arginine deprivation using ADI-PEG20 (pegargiminase) combined with
chemotherapy is untested in a randomized study among patients with cancer. ATOMIC …

Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a
promising therapeutic strategy. We here investigated the effect of the novel and highly …

Malignant pleural mesothelioma (MPM) is an aggressive cancer most commonly caused by
prior exposure to asbestos. Median survival is 12–18 months, since surgery is ineffective …